James Smith

James Smith is a Research Associate of the CASMI Translational Stem Cell Consortium, where his current research focuses on extracellular vesicle biomanufacturing, iPSC translation and several systematic reviews including immunotherapy, fracture healing, and the use of placebos in surgery. He recently completed a SENS Research Foundation Scholarship at the Harvard Stem Cell Institute and Jeff Karp’s Lab at the Brigham and Women’s Hospital, where he developed a computational model of extracellular vesicle bioprocessing costs. Aside from translational research, James has an active interest in basic biology, achieving a First Class undergraduate degree in Biological Sciences from the University of Oxford. You can find James on LinkedIn.

Posts by: James

Extracellular vesicles, the next Minions?

Author: James Smith, 06/28/16

This post was authored by Kelvin Ng and James Smith. Completing his PhD this year in the Karp lab at MIT/Harvard, Kelvin focuses on strategies and technologies that guide or accelerate the translation of therapeutic extracellular vesicles. His multidisciplinary research stems from a background in drug delivery, medical devices and cell therapy. Kelvin holds an…Read more

What do car (and CAR) choices have to do with cell therapies?

Author: James Smith, 03/07/16

Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical therapies. She is an associate at IP Asset Partnership Ltd in London, IP consultant to IP Asset Ventures…Read more

First gene therapy prescribed: How can we ensure there are more in the future?

Author: James Smith, 10/06/15

. With contributions from blogger David Brindley September 2015 has been an historic month for regenerative medicine. For the first time ever in the Western world, a prescription has been issued for a gene therapy, Glybera. At the ESGCT and FSGT Collaborative Congress, Helsinki, this news was welcomed and spurred discussion on broader challenges in…Read more

Travelling to another dimension: going from 2D to 3D cell culture

Author: James Smith, 01/26/15

With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that affect huge numbers of people. For these conditions, assuming that the treatment is effective, generating adequate quantities of…Read more

An “orchard” of cell production systems

Author: James Smith, 12/18/14

. With contributions from David Brindley Manufacturing may not be the first thing that springs to mind when regenerative medicine is mentioned. Most will think of the enormous potential for cell therapies or transplantation or editing of faulty genes. However, having attended the fifth annual Informa Life Sciences Cell Therapy Manufacturing conference, it is clear…Read more

The value of a cure

Author: James Smith, 12/11/14

. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York City that was referenced. It, therefore, seems appropriate to devote some time to the ‘other half:’…Read more

Surprising applications of economic thinking to scientific collaboration

Author: James Smith, 12/09/14

. With contributions from David Brindley. Suppose you are a talented fisherman and an outstanding shoe-maker. You have abandoned your dreams of a career in the regenerative medicine industry because, in one day, you can catch 100 fish or make one complete pair of shoes. That’s a very satisfying outcome for a day’s work. Your…Read more